# OnCo record advanced-cutaneous-scc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/advanced-cutaneous-scc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "advanced-cutaneous-scc" ;
  schema:name "Advanced cutaneous squamous cell carcinoma"@en ;
  schema:alternateName "Locally advanced cutaneous squamous cell carcinoma"@en, "Metastatic cutaneous squamous cell carcinoma"@en, "Advanced cSCC"@en, "Unresectable skin squamous cell carcinoma"@en ;
  schema:description "Advanced cutaneous squamous cell carcinoma is a skin cancer that has grown beyond what surgery or radiotherapy can remove or has spread to lymph nodes or organs. Because sun damage gives it more mutations than almost any other cancer, immunotherapy works well: cemiplimab or pembrolizumab shrinks about half of tumours, often for years, and cemiplimab before surgery can make large tumours vanish."@en ;
  schema:url <https://onco.cc/cancers/advanced-cutaneous-scc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Squamous-cell_carcinoma_of_the_skin> ;
  schema:citation <https://www.nejm.org/doi/full/10.1056/NEJMoa1805131>, <https://www.nejm.org/doi/full/10.1056/NEJMoa2209813>, <https://doi.org/10.1056/NEJMoa2502449>, <https://en.wikipedia.org/wiki/Squamous-cell_carcinoma_of_the_skin> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/cutaneous-scc/>, <https://onco.cc/cancers/head-and-neck/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/terms/mohs-surgery/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/superficial-radiotherapy/>, <https://onco.cc/technologies/oncolytic-virus/>, <https://onco.cc/technologies/photoimmunotherapy/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cosibelimab/>, <https://onco.cc/drugs/cetuximab/> ;
  onco:terms <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/pcr/> ;
  onco:trials <https://onco.cc/trials/empower-cscc-1/>, <https://onco.cc/trials/keynote-629/>, <https://onco.cc/trials/nct04050436/> ;
  onco:pipeline <https://onco.cc/trials/nct04050436/>, <https://onco.cc/trials/nct04305795/>, <https://onco.cc/trials/nct06585410/>, <https://onco.cc/drugs/hmbd-001/>, <https://onco.cc/drugs/cosibelimab/>, <https://onco.cc/drugs/vusolimogene-oderparepvec/>, <https://onco.cc/drugs/cemiplimab/> ;
  onco:standardOfCare <https://onco.cc/terms/mohs-surgery/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/trials/empower-cscc-1/>, <https://onco.cc/trials/keynote-629/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cosibelimab/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/trials/nct04050436/>, <https://onco.cc/trials/nct04305795/>, <https://onco.cc/drugs/vusolimogene-oderparepvec/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/cemiplimab/> .